Teva bids to buy BioXcel’s IGALMI asset for USD 57.5 million upfront, up to USD 67.5 million more
TEVA•Deal still depends on auction and court approval
The deal outcome hinges on auction results, bankruptcy court sign-off, higher bids, and customary closing conditions.
Asset includes IGALMI and FDA-review product BXCL501
The asset includes IGALMI, marketed for supervised use, with BXCL501 under FDA review for potential at-home treatment of agitation in adults.
The FDA target action date is set for Nov. 14, 2026; contingent payments are tied to approval timing and sales milestones.
Teva makes bid for BioXcel IGALMI asset in Chapter 11 sale
Teva bid to buy BioXcel’s dexmedetomidine sublingual film asset in a court-supervised Chapter 11 sale, not the whole company.
Offer terms call for a USD 57.5 million upfront payment for worldwide rights, with up to USD 67.5 million in contingent payments.
